Adaptimmune Therapeutics plc announced the appointment of Michael Garone as interim Chief Financial Officer (CFO) effective immediately. Since the early 2000s, Mike has held various CFO positions in the biotech and pharmaceutical industries. Most recently, Mike was CFO and interim CEO at Immunomedics Inc., (Morris Plains, NJ) where he supported the development phase of an Antibody Drug Conjugate (ADC) Oncology Product (IMMU-132/sacituzumab govitecan) for the treatment of a broad range of solid tumors. While there, he supported the raise of more than $700 million in public and private equity financings and a royalty financing. Prior to that, he was CFO at Emisphere Technologies Inc. (Roseland, NJ) from 2007 to 2016. Mike began his career as an OTC stock trader with Drexel Burnham Lambert in the early 1980s. From there, Mike went on to work at AT&T for twenty years where he held various positions of increasing responsibility including CFO of AT&T Alascom.